NEW YORK, Nov. 28 — Despite current economic conditions, Applied Biosystems remains optimistic about prospects for instrument sales, according to Stephen Lombardi, the company's vice president of applications and products. Speaking to a small early-morning audience of industry investors and analysts at the Robertson Stephens Medical Conference here on Wednesday, Lombardi said that NIH and pharma R&D spending continue to grow at rates in the range of 13 to 14 percent, and that’s good news for ABI. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.